Detalhe da pesquisa
1.
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
N Engl J Med
; 389(10): 877-888, 2023 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37351564
2.
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
Lancet
; 402(10400): 472-483, 2023 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37369232
3.
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
Diabetes Obes Metab
; 25(9): 2642-2649, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37264711
4.
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.
Diabetes Obes Metab
; 25(9): 2634-2641, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37344954
5.
The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.
Diabetes Obes Metab
; 24(1): 148-153, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34542221
6.
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.
Diabetes Obes Metab
; 22(12): 2451-2459, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33462955
7.
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
Diabetes Obes Metab
; 22(6): 938-946, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31984598
8.
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Lancet
; 392(10160): 2180-2193, 2018 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-30293770
9.
Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist.
Cell Metab
; 35(2): 274-286.e10, 2023 02 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36630958
10.
Community input in a genomic health implementation program: Perspectives of a community advisory group.
Front Genet
; 13: 892475, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35938017
11.
Modifications of IL-6 by Hypochlorous Acids: Effects on Receptor Binding.
ACS Omega
; 6(51): 35593-35599, 2021 Dec 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34984290
12.
Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
J Clin Endocrinol Metab
; 106(2): 388-396, 2021 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33236115
13.
Evaluation of a Genetics Education Program for Health Interpreters: A Pilot Study.
Front Genet
; 12: 771892, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-35186003
14.
Conformational changes in the Arp2/3 complex leading to actin nucleation.
Nat Struct Mol Biol
; 12(1): 26-31, 2005 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-15592479
15.
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.
Diabetes Care
; 43(6): 1352-1355, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32291277
16.
A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.
J Bone Miner Res
; 30(2): 216-24, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25196993
17.
The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density.
J Bone Miner Res
; 30(9): 1717-25, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25707611
18.
Teriparatide: A bone formation treatment for osteoporosis.
Drugs Today (Barc)
; 40(11): 935-48, 2004 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-15645006